Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 8, 2007, Pages 933-939

  Miele, E ^a   Pascarella, F ^a   Quaglietta, L ^a   Giannetti, E ^a   Greco, L ^a   Troncone, R ^a   Staiano, A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELLOBIOSE; MANNITOL; MESALAZINE; METHYLPREDNISOLONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; COLON; COLONOSCOPY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FEMALE; GASTROINTESTINAL ENDOSCOPY; HISTOLOGY; HUMAN; LABORATORY TEST; MALE; PERMEABILITY; PRIORITY JOURNAL; RELAPSE; SMALL INTESTINE; ULCERATIVE COLITIS;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CELLOBIOSE; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; DIURETICS, OSMOTIC; FEMALE; HUMANS; INFANT; INTESTINE, SMALL; MALE; MANNITOL; MESALAMINE; METHYLPREDNISOLONE; PERMEABILITY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECURRENCE;

EID: 34047127422     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03291.x     Document Type: Article

References (34)

1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am 1999; 28: 445-58.
2. Tibble JA, Sigthorsson G, Bridger B, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000; 119: 15-22.
3. Ruuska T, Vaajalahti P, Arajarvi P, et al. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1994; 19: 181-6.
4. Kaufman SS, Vanderhoof JA, Young R, et al. Gastroenteric inflammation in children with ulcerative colitis. Am J Gastroenterol 1997; 92: 1209-12.
5. Tobin JM, Sinha B, Ramani P, et al. Upper gastrointestinal mucosal disease in pediatric Crohn disease and ulcerative colitis: a blinded, controlled study. J Pediatr Gastroenterol Nutr 2001; 32: 443-8.
6. Kundhal PS, Stormon MO, Zachos M, et al. Gastric antral biopsy in the differentiation of pediatric colitides. Am J Gastroenterol 2003; 98: 557-61.
7. Parente F, Cucino C, Bollani S, et al. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role. Am J Gastroenterol 2000; 95: 705-11.
8. Sharif F, McDermott M, Dillon M, et al. Focally enhanced gastritis in children with Crohn's disease and ulcerative colitis. Am J Gastroenterol 2002; 97: 1415-20.
9. Abdullah BA, Gupta SK, Croffie JM, et al. The role of esophagogastroduodenoscopy in the initial evaluation of childhood inflammatory bowel disease: a 7-year study. J Pediatr Gastroenetrol Nutr 2002; 35: 636-40.
10. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
11. Jacobstein DA, Mamula P, Markowitz JE, Leonard M, Baldassano RN. Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J Clin Gastroenterol 2006; 40: 145-8.
12. Hildebrand HF, Holmquist B, Kristiansson L, et al. Chronic inflammatory bowel disease in children and adolescents in Sweden. J Pediatr Gastroenterol Nutr 1991; 13: 293-7.
13. Faubion WA, Loftus EV, Haremsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001; 121: 255-60.
14. Lichtiger S, Present D, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Eng J Med 1994; 330: 1841-5.
15. Russell GH, Katz AJ. Infliximab is effective in acute but no chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004; 39: 166-70.
16. Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice Dig Liv Dis 2004; 36: 767-70.
17. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006; 55: 1512-20.
18. Corcoran AC, Page IH. A method for the determination of mannitol in plasma and urine. Biol Che 1947; 170: 165-71.
19. Strobel S, Brydon WG, Ferguson A. Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut 1984; 25: 1241-6.
20. Troncone R, Mayer M, Mugione P, Cucciardi M, Abete A, Greco L. Cellobiose/mannitol sugar permeability test in children in relation to jejunal morphometry. Ital J Gastroenterol 1995; 27: 489-93.
21. Chong SK, Blackshaw AJ, Boyle S, William C, Walker-Smith JA. Histological diagnosis of chronic inflammatory bowel disease in childhood. Gut 1985; 26: 55-9.
22. Castellaneta SP, Afzal NA, Greenberg M, et al. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J Pediatr Gastro enterol Nutr 2004; 39: 257-61.
23. Snedecor GW, Cochran WG. Statistical methods. Iowa University Press, Ames, Iowa, USA, 2000.
24. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006; 4: 1124-9.
25. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Group d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994; 35: 231-5.
26. Monteleone G, Fina D, Caruso R, Pallone F. New mediators of immunity and inflammation in inflammatory bowel disease. Curr Opin Gastroenterol 2006; 22: 361-4.
27. Modigliani R, Mary JY, Simon JF, et al. Clinical biological and endoscopic picture of attacks of Crohn's disease; evolution on prednisolone. Gastroenterology 1990; 98: 811-8.
28. Landi B, Nguyen Anh T, Cortot A, et al. Endoscopic monitoring of Crohn's disease treatment: a prospective randomised clinical trial. The Group d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 1647-53.
29. Jorgensen LGM, Fredholm L, Petersen PH, Hey H, Munkholm P, Brandslund I. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)?. Clin Chem Lab Med 2005; 43: 403-11.
30. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is as stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 2005; 54: 364-8.
31. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993; 5: 79-84.
32. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the predictor of relapse in Crohn's disease. Lancet 1993; 341: 1437-9.
33. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin 6 production in Crohn's disease. Gastroenterology 1992; 102: 514-9.
34. Amit-Romach E, Reifen R, Uni Z. Mucosal function in rat jejunum and ileum is altered by induction of colitis. Int J Mol Med 2006; 18: 721-7.